{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:05:27Z","timestamp":1790809527587,"version":"4.1.0"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Stearoyl\u2010coenzyme A desaturase 1 (SCD\u20101) in sebaceous glands is a key enzyme in the synthesis of monounsaturated fatty acids essential for acne development. GSK1940029 gel, a novel SCD\u20101 inhibitor, is being developed as a potential treatment for acne. To assess the irritation potential, pharmacokinetics (PK), and safety of topical GSK1940029 to the skin of healthy adults, two interdependent studies were conducted in parallel. Study\u00a01 (n\u00a0=\u00a054) investigated the irritation potential of GSK1940029 (0.3% and 1%, occluded application) to allow for its application to larger surface areas in study 2 (n\u00a0=\u00a039), which investigated the safety, tolerability, and PK of GSK1940029 after single and repeat doses as occluded and nonoccluded applications. GSK1940029 was not a primary or cumulative irritant after 2 and 21 days of dosing in study 1. In study 2, single and repeat applications of GSK1940029 (0.1% to 1%) doses were well tolerated with little or no influence on AUC and C<jats:sub>max<\/jats:sub> under occluded or unoccluded conditions. Systemic exposure increased proportionally with surface area and was higher in occluded conditions. Design of these interdependent studies allowed for the assessment of the irritation potential for topical GSK1940029 in parallel with the investigation of PK and safety profiles.<\/jats:p>","DOI":"10.1002\/cpdd.644","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T20:33:31Z","timestamp":1547670811000},"page":"270-280","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Phase 1 Randomized, Placebo\u2010Controlled Trial With a Topical Inhibitor of Stearoyl\u2010Coenzyme A Desaturase 1 Under Occluded and Nonoccluded Conditions"],"prefix":"10.1002","volume":"8","author":[{"given":"Richard A.","family":"Brigandi","sequence":"first","affiliation":[{"name":"Virtual Proof of Concept Discovery Performance Unit GlaxoSmithKline  King of Prussia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation GlaxoSmithKline  King of Prussia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Murnane","sequence":"additional","affiliation":[{"name":"Virtual Proof of Concept Discovery Performance Unit GlaxoSmithKline  King of Prussia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Ann","family":"Reedy","sequence":"additional","affiliation":[{"name":"Virtual Proof of Concept Discovery Performance Unit GlaxoSmithKline  King of Prussia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Shakib","sequence":"additional","affiliation":[{"name":"CMAX a division of IDT Australia Limited  Adelaide South Australia Australia"},{"name":"Department of Clinical Pharmacology School of Medicine University of Adelaide  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.03.052"},{"key":"e_1_2_9_3_1","first-page":"582","article-title":"Pathogenesis of acne vulgaris: What's new, what's interesting and what may be clinically relevant","volume":"10","author":"Bellew S","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.019"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09878.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3514"},{"issue":"2","key":"e_1_2_9_7_1","first-page":"S3","article-title":"The use of isotretinoin in the treatment of acne vulgaris clinical considerations and future directions","volume":"7","author":"Leyden JJ","year":"2014","journal-title":"J Clin Aesthet Dermatol."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2009.12.002"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2015.08.018"},{"key":"e_1_2_9_10_1","volume-title":"Draft Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products","author":"Food and Drug Administration","year":"1999"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/srt.12118"},{"key":"e_1_2_9_12_1","first-page":"S99","article-title":"Development of a plasma\/dermis population pharmacokinetic model for GSK1940029","volume":"42","author":"Zhu J","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.644","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:57:41Z","timestamp":1694368661000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/cpdd.644"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.644","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"2017-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}